Clorox Co
Change company Symbol lookup
Select an option...
CLX Clorox Co
COP ConocoPhillips
FBP First Bancorp
PTCT PTC Therapeutics Inc
ROKU Roku Inc
WORK Slack Technologies Inc
ARKW ARK Next Generation Internet ETF
SPOT Spotify Technology SA
GBTC Grayscale Bitcoin Trust (BTC)
ARKK ARK Innovation ETF
Go

Consumer Staples : Household Products | Mid Cap Blend
Company profile

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International. Its Cleaning segment consists of laundry, home care and professional products marketed and sold in the United States. Its Household segment consists of charcoal, cat litter and plastic bags, wraps and container products marketed and sold in the United States. Its Lifestyle segment consists of food products, water-filtration systems and filters, and natural personal care products marketed and sold in the United States. Its International segment consists of products sold outside the United States. It markets some of the consumer brand names, such as namesake bleach and cleaning products, Pine-Sol cleaners, Liquid-Plumr clog removers and Kingsford charcoal.

Closing Price
$197.52
Day's Change
1.97 (1.01%)
Bid
--
Ask
--
B/A Size
--
Day's High
199.28
Day's Low
194.74
Volume
(Heavy Day)
Volume:
1,740,088

10-day average volume:
1,348,784
1,740,088

UPDATE: Quest Diagnostics shares jump 3.8% premarket as earnings beat on demand for COVID-19 tests

7:26 am ET October 22, 2020 (MarketWatch)
Print

Quest Diagnostics Inc. shares (DGX) jumped 3.8% in premarket trade Thursday, after the company beat third-quarter earnings estimates and raised guidance, buoyed by demand for COVID-19 testing. Secaucus, N.J.-based Quest said it had net income of $568 million, or $4.14 a share, in the quarter, up from $215 million, or $1.56 a share, in the year-earlier period. Adjusted per-share earnings came to $4.31, ahead of the $3.72 FactSet consensus. Revenue rose to $2.786 billion from $1.956 billion, also ahead of the $2.722 billion FactSet consensus. "Quest had a very strong third quarter, benefiting from continued demand for COVID-19 testing and the rapid recovery of health care utilization," Chief Executive Steve Rusckowski said in a statement. "Quest Diagnostics. "Quest has performed over 22 million COVID-19 molecular and serology tests to date, more than any other provider." The company is seeing signs that the health care system is returning to pre-pandemic levels, as base testing volume, excluding COVID-19 molecular and antibody testing, continued to recover through the quarter. "We are grateful for the CARES Act funding that provided our company with support earlier this year at a time of great uncertainty for our nation," said Rusckowski. "Several months into this pandemic, we do not require this funding. As a result, we believe returning these funds to the government now is the right thing to do." The company raised its guidance and now expects revenue to range from $8.8 billion to $9.1 billion, up from prior guidance of $8.4 billion to $8.8 billion. It expects adjusted EPS of $9.00 to $10.00, compared with prior guidance of $7.50 to $9.00. The FactSet consensus is for EPS of $8.82 and sales of $8.8 billion. Shares have gained 15% in the year to date, while the S&P 500 has gained 6.3%.

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 22, 2020 07:26 ET (11:26 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.